DRREDDY:NSE
Dr Reddy's Laboratories Ltd
1 199,80 ₹
arrow_upward
+1,68%(+19,80) 1D
9 қаз., 15:30:00 GMT+5:30 · INR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DRREDDY...
Open
1 180,00 ₹
High
1 200,80 ₹
Low
1 172,00 ₹
Mkt. cap
997,09 млрд
Avg. vol.
1,81 млн
Volume
1,51 млн
Dividend
0,67%
Quarterly dividend
2,00 ₹
Ex-dividend date
2026 ж. 10 шіл.
P/E ratio
31,03
52-wk high
1 414,90 ₹
52-wk low
1 101,00 ₹
EPS
38,67 ₹
Shares outstanding
166,06 млн
No. of employees
28 мың
Open
1 180,00 ₹
High
1 200,80 ₹
Low
1 172,00 ₹
Mkt. cap
997,09 млрд
Avg. vol.
1,81 млн
Volume
1,51 млн
Dividend
0,67%
Quarterly dividend
2,00 ₹
Ex-dividend date
2026 ж. 10 шіл.
P/E ratio
31,03
52-wk high
1 414,90 ₹
52-wk low
1 101,00 ₹
EPS
38,67 ₹
Shares outstanding
166,06 млн
No. of employees
28 мың
News stories
From web sources and news partners
Cryptonews.net
·
34 минут бұрын
XRP Price Prediction Ahead of Tomorrow’s Expected XRPN Nasdaq Debut
Barchart.com
·
1 сағат бұрын
The S&P 500 Is Near Record Highs. So Why Does Your Portfolio Feel Like a Bear Market?
FXLeaders
·
14 минут бұрын
Dow Jones and Nasdaq Futures Start Higher Ahead of US Inflation Data
Yahoo Finance
·
9 сағат бұрын
Pokémon Cards Just Crushed Bitcoin, Gold and the S&P 500 With 150% Returns
Profile
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
About Dr Reddy's Laboratories Ltd
CEOErez Israeli
Employees27,5 мың
Founded1984
HeadquartersХайдарабад, Андхра-Прадеш, Үндістан
SectorPharmaceutical industry
Websitedrreddys.com